Pharmaceutical company Pharmaxis (ASX: PXS) today welcomed an announcement by the Federal government that Bronchitol will be listed on the Australian Pharmaceutical Benefits Scheme (PBS) for the treatment of cystic fibrosis.

The Minister for Health Tanya Plibersek has announced Bronchitol will be reimbursed for the treatment of cystic fibrosis (CF) patients, including children older than six years, who cannot use or are nonresponsive to medicines already listed on the PBS.

Dr Alan Robertson, the CEO of Pharmaxis said: “Cystic fibrosis is a challenging disease to treat and Bronchitol represents the first new drug ever listed on the PBS to tackle the fundamental problem responsible for loss of lung function. We are pleased that this innovation will shortly be available to patients through the Pharmaceutical Benefits Scheme and look forward to monitoring the impact of Bronchitol on people’s lives over the coming years. This reimbursement decision is a testament to the dedication of the many people involved in developing Bronchitol for cystic fibrosis and we welcome the news.”

Mr David Jack, CEO of Cystic Fibrosis Australia said: “New therapeutic advances are desperately needed and the PBS listing is excellent news. I am pleased for the CF Community that a product of Australian research and innovation has brought a significant advance in patient care. Improving lung function and preventing lung infections are key to maintaining good health, so new treatment options have the potential to make a real difference in the lives of CF patients.”

When listed, the approved price of Bronchitol will be $31.00 per day.

More than 600 cystic fibrosis patients were part of two large scale clinical trials of Bronchitol. The clinical trials were managed by Pharmaxis which coordinated studies in 95 hospitals and CF centres throughout the world.

Bronchitol is approved for marketing in Australia and Europe and a New Drug Application has been lodged with the FDA seeking marketing approval in the USA.


no comment untill now

Sorry, comments closed.